

Marta Cremonesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2505204/publications.pdf>

Version: 2024-02-01

37
papers

1,468
citations

304743

22
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

1574
citing authors

#	ARTICLE	IF	CITATIONS
1	Receptor-mediated radiotherapy with ⁹⁰ Y-DOTA-D-Phe ¹ -Tyr ³ -octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 426-434.	2.1	186
2	Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 348-357.	6.4	172
3	Dosimetry in Peptide radionuclide receptor therapy: a review. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1467-75.	5.0	131
4	Biokinetics and dosimetry in patients administered with ¹¹¹ In-DOTA-Tyr 3 -octreotide: implications for internal radiotherapy with ⁹⁰ Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 877-886.	6.4	122
5	Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 110-120.	6.4	80
6	Radioembolisation with ⁹⁰ Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2088-2096.	6.4	65
7	Radiation protection in radionuclide therapies with ⁹⁰ Y-conjugates: risks and safety. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1321-1327.	6.4	54
8	Role of interim ¹⁸ F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1915-1927.	6.4	53
9	Radioguided Sentinel Node Biopsy to Avoid Axillary Dissection in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 28-31.	1.5	52
10	Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. <i>Thoracic Surgery Clinics</i> , 2014, 24, 333-349.	1.0	52
11	High-Dose Radioimmunotherapy with ⁹⁰ Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1871-1879.	5.0	49
12	Interim ¹⁸ F-FDG PET/CT During Chemoradiation Therapy in the Management of Head and Neck Cancer Patients: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 555-573.	0.8	34
13	Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?. <i>Medical Oncology</i> , 2020, 37, 29.	2.5	34
14	Recent Radiomics Advancements in Breast Cancer: Lessons and Pitfalls for the Next Future. <i>Current Oncology</i> , 2021, 28, 2351-2372.	2.2	32
15	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). <i>European Radiology</i> , 2021, 31, 716-728.	4.5	31
16	Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1336-1339.	6.4	30
17	Cerenkov and radioluminescence imaging of brain tumor specimens during neurosurgery. <i>Journal of Biomedical Optics</i> , 2016, 21, 050502.	2.6	30
18	Interim ¹⁸ F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 125, 200-212.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Translational and rotational localization errors in cone-beam CT based image-guided lung stereotactic radiotherapy. <i>Physica Medica</i> , 2016, 32, 859-865.	0.7	27
20	PETER PHAN: An MRI phantom for the optimisation of radiomic studies of the female pelvis. <i>Physica Medica</i> , 2020, 71, 71-81.	0.7	27
21	Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer. <i>Tumori</i> , 1997, 83, 539-541.	1.1	25
22	A multicenter study on radiomic features from T2-weighted images of a customized MR pelvic phantom setting the basis for robust radiomic models in clinics. <i>Magnetic Resonance in Medicine</i> , 2021, 85, 1713-1726.	3.0	22
23	Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis. <i>Cancers</i> , 2021, 13, 4271.	3.7	18
24	Therapeutic schemes in ¹⁷⁷ Lu and ⁹⁰ Y-PRRT: radiobiological considerations. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 216-231.	0.7	15
25	TestDose: A nuclear medicine software based on Monte Carlo modeling for generating gamma camera acquisitions and dosimetry. <i>Medical Physics</i> , 2015, 42, 6885-6894.	3.0	12
26	High Dose Zevalin (⁹⁰ Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.. <i>Blood</i> , 2005, 106, 488-488.	1.4	12
27	Interim ¹⁸ F-FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 28-42.	4.4	11
28	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. <i>Blood</i> , 2006, 108, 2720-2720.	1.4	11
29	HeLLePhant: A phantom mimicking non-small cell lung cancer for texture analysis in CT images. <i>Physica Medica</i> , 2022, 97, 13-24.	0.7	9
30	Yttrium-Based Therapy for Neuroendocrine Tumors. <i>PET Clinics</i> , 2014, 9, 71-82.	3.0	8
31	In Silico Validation of MCID Platform for Monte Carlo-Based Voxel Dosimetry Applied to ⁹⁰ Y-Radioembolization of Liver Malignancies. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1939.	2.5	8
32	Cone-beam CT-based inter-fraction localization errors for tumors in the pelvic region. <i>Physica Medica</i> , 2018, 46, 59-66.	0.7	6
33	Dosimetric Issues Associated with Percutaneous Ablation of Small Liver Lesions with ⁹⁰ Y. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6605.	2.5	3
34	High Dose ⁹⁰ Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. <i>Blood</i> , 2007, 110, 1890-1890.	1.4	3
35	Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose ⁹⁰ Y - Ibritumomab Tiuxetan.. <i>Blood</i> , 2008, 112, 2187-2187.	1.4	2
36	The Role of Acquisition Angle in Digital Breast Tomosynthesis: A Texture Analysis Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6047.	2.5	1

#	ARTICLE	IF	CITATIONS
37	Authors' Reply to: Radiobiology as a Basic and Clinical Medical Science: What the Physicists have Forgotten. Tumori, 2016, 102, e9-e9.	1.1	0